UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January ~~September 21~~3, ~~2012~~2013

MedClean Technologies, Inc.

(Exact name of registrant as specified in its charter)

Delaware	000-03125	21-0661726
(State or other jurisdiction	(Commission File Number)	(I.R.S. Employer
of incorporation)		Identification Number)

57 S Commerce Way

Suite 310

Bethlehem, PAPennsylvania 18017

(Address of principal executive offices, including zip code)

1(203) 798-~~888-777-4077~~1080

(Registrant'’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o [ ] Pre-commencement ~~communications~~ communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o [ ] Pre-commencement ~~communications~~ communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 53.0203 ~~Departure~~Material ofModification ~~Directors~~to orRights ~~Certain Officers; Election~~ of ~~Directors;~~Security ~~Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.~~Holders

~~Resignation~~On January 3, 2013, MedClean Technologies, Inc. (the “Corporation”) filed a certificate of ~~Director~~designations, rights and preferences (the “Certificate of Designation”) with the Secretary of State of the State of Delaware pursuant to which the Corporation set forth the designation, powers, rights, privileges, preferences and restrictions of the Series D Preferred Stock. Among other things, each one (1) share of the Series D Preferred shall have voting rights equal to (x) 0.019607 multiplied by the total issued and outstanding shares of Common Stock eligible to vote at the time of the respective vote (the “Numerator”), divided by (y) 0.49, minus (z) the Numerator. For purposes of illustration only, if the total issued and outstanding shares of Common Stock eligible to vote at the time of the respective vote is 5,000,000, the voting rights of one share of the Series D Preferred shall be equal to 102,036 (((0.019607 x 5,000,000) / 0.49) – (0.019607 x 5,000,000) = 102,036).

OnThe ~~September~~foregoing ~~21,~~description ~~2012, David Laky resigned from his positions as Chief Executive Officer and President. Mr. Laky will continue to serve as a director~~ of the ~~Company~~Series ~~and~~D ~~shall~~Preferred ~~serve~~Stock asdoes ~~the~~not ~~Company’s~~purport ~~Executive~~to ~~until~~be ~~the~~complete ~~Board~~and ofis ~~Directors~~subject ~~(the “Board”) has identified a new Chief Executive Officer. Jay S. Bendis will continue~~ to, serve the Company as a director but shall temporarily resign as Chairman of the Board until such time as the Company can find a suitable replacement for Mr. Laky. The Board will immediately commence the search for a new Chief Executive Officer and ~~anticipates~~qualified ~~completing~~in its ~~search~~entirety ~~no later than January 1~~by, ~~2013. The resignation is not~~ the ~~result~~ Certificate of ~~any disagreement with the Company on any matter relating to the Company’s operations~~Designation, ~~policies~~a ~~or practices. A~~ copy of ~~Mr.~~of ~~Laky’s~~which ~~resignation letter~~ is attached hereto as Exhibit 1799.1 and incorporated herein ~~in its entirety~~ by reference.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.		Description
17.1		Resignation Letter of David Laky, dated September 21, 2012
99.1		Certificate of Designations, Rights and Preferences of Series D Preferred Stock filed with the Secretary of State of the State of Delaware on January 3, 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.

	MEDCLEAN TECHNOLOGIES, INC.		~~MEDCLEAN TECHNOLOGIES, INC.~~
Dated: September 24, 2012			By:	/s/ David Laky
Dated: February 1, 2013	By:	/s/ David Laky
				Name: David Laky
	Name:	David Laky
				Title: Executive Chairman
	Title:	Executive Chairman

Filing Compare · MedClean Technologies, Inc.